Keytruda Injectable Product

DRUG3 trials

Sponsors

PDC*line Pharma SAS, Rampart Health, L.L.C., ImmunSYS, LLC

Conditions

Metastatic CancerNon Small Cell Lung Cancer

Phase 1

Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

Active, not recruitingNCT03970746

PDC*line Pharma SASNon Small Cell Lung Cancer

Start: 2019-09-10End: 2025-12-31Updated: 2025-05-29

Phase 2

A Phase 2 Trial for Patients With Metastatic Solid Cancer

Active, not recruitingNCT04713371

Rampart Health, L.L.C.Metastatic Cancer

Start: 2021-05-19End: 2024-12-31Target: 32Updated: 2024-05-09

Metastatic Solid Cancer Clinical Trial

Active, not recruitingNCT04739618

ImmunSYS, LLCMetastatic Cancer

Start: 2021-03-04End: 2024-12-31Target: 32Updated: 2024-07-23

Related Papers

First-in-Human Phase II Clinical Trial of Multiplex IntraTumoral Immunotherapy (MITI) in Patients with Metastatic Solid Cancer (Abscopal 5001 Trial)

Cancers2025-09-12

Abstract 1182: PDC*lung01: An innovative therapeutic cancer vaccine induces specific immune responses in combination with anti- PD-1 treatment in patients with non-small cell lung cancer

Cancer Research2024-03-22

706 First-in-human phase 2 clinical trial of multiplex combination intratumoral immunotherapy (MCII) in patients with metastatic solid cancer (Abscopal 5001 trial)

Regular and Young Investigator Award Abstracts2023-10-311 citations